UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses

Wagstaffe, HR; Clutterbuck, EA; Bockstal, V; Stoop, JN; Luhn, K; Douoguih, MJ; Shukarev, G; ... Goodier, M; + view all (2020) Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses. Journal of Clinical Investigation 10.1172/JCI132438. (In press). Green open access

[thumbnail of Ebola GP IL-18_HW_preprint.pdf]
Preview
Text
Ebola GP IL-18_HW_preprint.pdf - Accepted Version

Download (1MB) | Preview

Abstract

BACKGROUND: NK cells are activated by innate cytokines and viral ligands to kill virus-infected cells; these functions are enhanced during secondary immune responses and after vaccination by synergy with effector T cells and virus-specific antibodies. In human Ebola virus infection, clinical outcome is strongly associated with the initial innate cytokine response, but the role of NK cells has not been thoroughly examined. METHODS: The novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 3 studies. Here, we analysed NK cell phenotype and function in response to Ad26.ZEBOV, MVA-BN-Filo vaccination regimen, and in response to in vitro Ebola glycoprotein stimulation of PBMC isolated before and after vaccination. RESULTS: We show enhanced NK cell proliferation and activation after vaccination compared with baseline. Ebola glycoprotein-induced activation of NK cells was dependent on accessory cells and TLR-4-dependent innate cytokine secretion (predominantly from CD14+ monocytes) and enriched within less differentiated NK cell subsets. Optimal NK cell responses were dependent on IL-18 and IL-12, whilst IFN-γ secretion was restricted by high concentrations of IL-10. CONCLUSION: This study demonstrates the induction of NK cell effector functions early after Ad26.ZEBOV, MVA-BN-Filo vaccination and provides a mechanism for the activation and regulation of NK cells by Ebola GP. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02313077. FUNDING: U.K. Medical Research Council Studentship in Vaccine Research, Innovative Medicines Initiative 2 Joint Undertaking, EBOVAC (Grant 115861) and Crucell Holland (now Janssen Vaccines & Prevention B.V.), European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).

Type: Article
Title: Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1172/JCI132438
Publisher version: https://doi.org/10.1172/JCI132438
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
URI: https://discovery.ucl.ac.uk/id/eprint/10096164
Downloads since deposit
55Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item